0.00Open0.40Pre Close0 Volume6 Open Interest6.00Strike Price0.00Turnover114.10%IV1.41%PremiumOct 4, 2024Expiry Date0.32Intrinsic Value100Multiplier2DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type-0.7208Delta0.6824Gamma14.20Leverage Ratio-0.0416Theta-0.0002Rho-10.24Eff Leverage0.0015Vega
Inovio Pharmaceuticals Stock Discussion
On Friday, the fear of human-to-human spread grew ever so slightly: The CDC confirmed that four health-care workers in Missouri had fallen sick after caring for a patient who was infected with bird flu.
https://www.msn.com/en-us/health/other/bird-flu-pandemic-fears-skyrocket-as-us-identifies-first-cases-of-possible-human-to-human-transmission/ar-AA1rwhf5?ocid=BingNewsSerp
Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet